CN101773518A - Medicine for treating infectious diseases - Google Patents
Medicine for treating infectious diseases Download PDFInfo
- Publication number
- CN101773518A CN101773518A CN201010112871A CN201010112871A CN101773518A CN 101773518 A CN101773518 A CN 101773518A CN 201010112871 A CN201010112871 A CN 201010112871A CN 201010112871 A CN201010112871 A CN 201010112871A CN 101773518 A CN101773518 A CN 101773518A
- Authority
- CN
- China
- Prior art keywords
- zinc
- base
- treatment
- montmorillonitum
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a medicine for treating infectious diseases, in particular to a medicine prepared by zinc-base montmorillonite and used to treat infectious diseases such as upper respiratory tract infection, digestive tract infection, genital tract infection, skin infection and the like. The invention has the advantages that bacteria and virus drug resistance is not caused and the medicine is still effective on infection caused by drug-resistant bacteria and drug-resistant viruses.
Description
Invention field
The present invention relates to medicine, be specifically related to a kind of medicine for the treatment of infectious diseases, particularly the zinc-base Montmorillonitum is in the medicine and the using method that are used to prevent and treat infectious disease such as upper respiratory tract infection, digestive tract infection, reproductive tract infection, skin infection.
Background of invention
Upper respiratory tract infection, digestive tract infection, reproductive tract infection, skin infection are common infectious disease.Along with the modern medicine science and technology development, the antibiotic of a new generation is continually developed and is used widely clinical, on the one hand enlarged the medication range of choice that the medical worker treats infectious disease, improved the cure rate of bacterial infection disease greatly, thereby made mortality rate be reduced to reduced levels.But then, the extensive use of broad ectrum antibiotic of new generation even abuse have brought a series of thorny medical treatment and even social problem.In many countries and regions, antibacterial is serious day by day to the drug resistance phenomenon of common antibiotics even new antibiotic, has proposed new challenge to clinical drug therapy, has also caused huge medical expense.How overcoming the bacterial resistance phenomenon then is the important research section topic of pendulum in face of us.
The medicine of upper respiratory tract infection, digestive tract infection, reproductive tract infection, skin infection mostly is oral and injection, and medicine is through absorbing the distribution whole body, and at upper respiratory tract, concentration is low, weak curative effect.
Be symmetric dioctahedron on the Montmorillonitum space structure, be lamellar under the scanning electron microscope.Internal structure is because Al
3+To some extent by Mg
2+Deng replacement, cause the imbalance of internal charge, three charge-sites of corresponding formation, promptly in the layer, interlayer and layer are held, in its middle level and the charged negativity of interlayer, and layer end positively charged, for balancing charge, Montmorillonitum just has the characteristic of absorption cation to interlayer, and as long as cation (no matter organic cation or inorganic cation) concentration is higher than the cationic concentration of its interlayer in the medium of living in, the ion in the interlamination region will be exchanged.According to the tradable sodium in the interlamination region, calcium, hydrionic kind, natural Montmorillonitum has sodium montmorillonite, ca-montmorillonite.Using at field of medicaments at present mainly is ca-montmorillonite, as adsorbent and mucosa protective agent, orally is used for the treatment of the acute and chronic diarrhoea that a variety of causes causes.
Zinc is one of trace element of needed by human, composition as plurality of enzymes participates in various metabolic activities widely, have the virus of inhibition, strengthen local immunity with effects such as control bacterial overgrowth and early stage pathogen removings, zinc gluconate is used for the treatment of flu and diarrhoea clinically.
Also there is not the zinc-base Montmorillonitum to be used for preventing and treating the report of infectious disease such as pathogenic bacteria, disease of viral infection, particularly upper respiratory tract infection, digestive tract infection, reproductive tract infection, skin infection at present.
Summary of the invention
The objective of the invention is to overcome the deficiency of existing technology, provide a kind of antibacterial, virus not to produce the drug resistance phenomenon, drug-resistant bacteria, viral infection are effectively treated the medicine of infectious disease.Especially for the medicine that prevents and treat infectious disease such as upper respiratory tract infection, digestive tract infection, reproductive tract infection, skin infection.
Another object of the present invention is to provide a kind of preparation method of zinc-base Montmorillonitum.
The present invention also provides the zinc-base Montmorillonitum in the pharmacy type and the using method that are used to prevent and treat infectious disease such as upper respiratory tract infection, digestive tract infection, reproductive tract infection, skin infection.
The object of the present invention is achieved like this:
A kind of medicine for the treatment of infectious diseases is characterized in that with zinc-base smectite in treatment infectious disease.Prevent and treat infectious disease such as upper respiratory tract infection, digestive tract infection, reproductive tract infection, skin infection especially for the zinc-base Montmorillonitum.
The preparation method of zinc-base Montmorillonitum: the Montmorillonitum after will purifying, add entry, stir evenly, use ultrasonic dispersing, add water-soluble zinc salt, the amount of zinc ion surpasses the ion exchange capacity of Montmorillonitum, stirs, after centrifugal the dewatering, wash the acid group reaction of not having zinc salt to cleaning mixture with water, dewater, oven dry, levigate promptly makes the zinc-base Montmorillonitum.
With zinc-base smectite in treatment infectious disease, its pharmaceutical dosage form is suspensoid, gel, ointment, suppository, membrane, tablet and powder.
With zinc-base smectite in treatment upper respiratory tract infection, its pharmaceutical dosage form is suspensoid, gel and powder.
With zinc-base smectite in treatment digestive tract infection, its pharmaceutical dosage form is suspensoid, gel, tablet and powder.
With zinc-base smectite in treatment reproductive tract infection, its pharmaceutical dosage form is suspensoid, gel, membrane, ointment and suppository.
With zinc-base smectite in treatment skin infection, its pharmaceutical dosage form is suspensoid, gel, membrane, ointment and powder.
The concentration of zinc-base smectite suspension agent of the present invention is that the content of zinc-base Montmorillonitum is the 5-20 gram in per 100 ml of formulation; The concentration of zinc-base montmorillonite gelling is that the amount that contains the zinc-base Montmorillonitum in per 100 milliliters of zinc-base montmorillonite gellings is the 10-30 gram; Zinc-base Montmorillonitum suppository is that every suppository contains zinc-base Montmorillonitum 0.5-3 gram.
During with zinc-base smectite in treatment upper respiratory tract infection, suspensoid, gel can spray into nasal cavity or splash into nasal cavity in this way, also can splash into or spray into pharyngeal, and the 0.1-0.2 milliliter is sprayed in each 1-3 spray at every turn, in this way powder can spray into nasal cavity or spray into pharyngeal, every day 2-6 time.
During with zinc-base smectite in treatment digestive tract infection, its suspensoid, gel, tablet and powder all are oral, and each taking dose is to contain zinc-base Montmorillonitum 1-3 gram, every day 3 times.
During with zinc-base smectite in treatment reproductive tract infection, its suspensoid, gel, ointment and suppository all are vagina medicinals, and every day 1-2 time, every consumption is to contain zinc-base Montmorillonitum 0.5-3 gram.
During with zinc-base smectite in treatment skin infection, its suspensoid, gel, ointment and powder all are in affected part local application, every day 1-2 time.
Upper respiratory tract infection of the present invention is meant common cold, influenza, acute pharyngitis, tonsillitis, acute laryngitis, acute sinusitis.
Digestive tract infection of the present invention is meant acute and chronic diarrhoea, oral ulcer that a variety of causes causes.
Reproductive tract infection of the present invention is meant the vaginal infection disease, comprising: bacterial vaginosis, viral vaginitis, monilial vaginitis, senile vaginitis.
Skin infection of the present invention is meant epidermis ulcer, ecthyma.
Substantive progress of the present invention is Montmorillonitum and zinc ion are combined; Montmorillonitum not only can be brought into play absorbing pathogenic bacteria, virus and various toxin; the effect of the protection mucosa and the face of infection; but also be the carrier of zinc ion transmission system; the zinc-base Montmorillonitum can discharge zinc ion according to the cation concn that uses the position, reaches controlled release, long lasting purpose.The importance of zinc in the human life activity extensively is familiar with, but trace element zinc is not " nutriment ", excessive use or local concentration are too high can to cause the human body zinc poisoning, and cause a series of diseases, zinc-base Montmorillonitum controlled release zinc ion of the present invention, promptly brought into play the collaborative pharmacological action of Montmorillonitum and zinc ion, can prevent zinc ion concentration again in vivo or local exceeding for the moment, and produce toxic and side effects.
With Montmorillonitum and zinc ion treatment infectious disease, antibacterial, virus do not produce drug resistance, and other antimicrobial drugs are produced the infectious disease that chemical sproof antibacterial, virus cause, the zinc-base Montmorillonitum is still effective.
The specific embodiment:
With Montmorillonitum, add 8-15 times of water gaging, stir evenly, handle with the 18-40KHz ultrasonic echography and handled in 30-120 minute, add water-soluble zinc salt zinc sulfate or water-soluble zinc salts such as zinc chloride or zinc nitrate or zinc gluconate, adding zinc ion amount is 1.5-3 a times of Montmorillonitum ion exchange capacity, stirs 12-24 hour, after centrifugal the dewatering, wash with water 2-3 time, dewater, 100 ℃ of oven dry, levigate promptly make the zinc-base Montmorillonitum.
Get the zinc-base Montmorillonitum, commonly used preparation method in the with medicament adds or does not add adjuvant, makes suspensoid, gel, ointment, suppository, membrane, tablet and powder.Be used for the treatment of infectious disease.Particularly prevent and treat infectious disease such as upper respiratory tract infection, digestive tract infection, reproductive tract infection, skin infection.
Experimental example 1: zinc-base smectite suspension agent collunarium is to the preventive effect of influenza virus A type (flu-A) infecting mouse.
Mice is divided into blank group, model group, Ribavirin Nasal Drops group and zinc-base smectite suspension agent 5%, 10%, 20% (g/ml) dosage group, totally 6 groups, 30 every group at random.Ribavirin Nasal Drops collunarium every day 3 times, each 0.05 milliliter.Zinc-base smectite suspension agent collunarium collunarium every day 3 times, each 0.05 milliliter, blank group and model group give the normal saline of equivalent.Successive administration 2 days.
Administration the 2nd day, except that the normal control group, each is organized mice and infects every (inferior) 0.05 milliliter with 15 LD50 influenza virus collunariums.
The result: the blank group mice mental status is good, alertness, and movable quick, hair is glossy, and diet is good, and eupnea, body weight increase naturally.The 1st day Non Apparent Abnormality symptom of model group mice all had asthenia on the 2nd day slightly, and hair occurs in disorder, gradually the loss of gloss pool, rapid breathing is not liked activity, and easily frightened, whole above-mentioned symptoms increased the weight of in the 3rd day, beginning is dead, the spasm symptom that has a convulsion when dead, seven days dead 26.Ribavirin Nasal Drops group mice behind viral infection, all occurred in the 3rd day hair in disorder, be slow in action, symptom such as rapid breathing, symptom disappears substantially after the 7th day, seven days dead 3.Each concentration group of zinc-base smectite suspension agent 5%, 10%, 20% (g/ml) began to occur hair number of elements in disorder, that roll up, do not like symptoms such as activity, rapid breathing on the 3rd day behind viral infection be 10,5,3, other mice Non Apparent Abnormality symptoms, dead number of elements takes place each concentration group is 2,2,0.
Presentation of results zinc-base Montmorillonitum infects influenza virus A type (flu-A) extraordinary preventive effect, can be used for flu-prevention.
Experimental example 2: zinc-base montmorillonite gelling collunarium is to the therapeutical effect of influenza virus A type (flu-A) infecting mouse.
Mice is divided into 6 groups at random, 30 every group.Stay to the normal control group except that one group, other are respectively organized mice and infect every (inferior) 0.05 milliliter with 15 LD50 influenza virus collunariums.
Observe and find that the normal control group mice mental status is good, alertness, movable quick, hair is glossy, and diet is good, and eupnea, body weight increase naturally.Other respectively organize the 1st day Non Apparent Abnormality symptom of mice, and asthenia was all arranged on the 2nd day slightly, and hair occurs in disorder, loss of gloss pool gradually, and rapid breathing is not liked activity, and is easily frightened.
The 2nd day begins the administration of dividing into groups, the Ribavirin Nasal Drops group, and every day, collunarium was 3 times, each 0.05 milliliter; Zinc-base montmorillonite gelling 10%, 20%, 30% (g/ml) dosage group, every day, collunarium was 3 times, each 0.05 milliliter; Normal control group and model group give the normal saline of equivalent.Successive administration 5 days; Administration finishes statistics and respectively organizes the dead mouse situation, and the normal control group does not have death as a result, mortality rate 0%; Dead 26 of model group, mortality rate 86.7%; Dead 5 of Ba Weilin nasal drop group, mortality rate 16.7%; Dead 7 of zinc-base montmorillonite gelling 10% (g/ml) dosage group, mortality rate 23.3%; Dead 4 of zinc-base montmorillonite gelling 20% (g/ml) dosage group, mortality rate 13.3%; Dead 4 of zinc-base montmorillonite gelling 30% (g/ml) dosage group, mortality rate 13.3%.Presentation of results zinc-base montmorillonite gelling collunarium has extraordinary therapeutical effect to influenza virus A type (flu-A) infecting mouse, can be used for treating influenza.
Experimental example 3: zinc-base smectite in treatment influenza clinical trial.
Volunteer's 238 examples, (1) have flu patient contact history; (2) febris acuta, fear of cold, the dried pain of itching of bottleneck throat appear, with other symptoms such as cough, nasal obstruction watery nasal discharges; (3) check pharyngeal obvious hyperemia or antiadoncus, hyperemia; (4) blood testing checks that numeration of leukocyte is normal or on the low side, and percentage of lymphocyte raises; (5) get rid of the infection at other position.
With pack into spray bottle of zinc-base smectite suspension agent, make spray.104 routine patients with 10% (g/ml), 67 routine patients with 15% (g/ml), 62 routine patients are with the zinc-base Montmorillonitum spray of 20% (g/ml), the patient is sprayed medicine and preceding sparing nasal cavity is cleaned out, the nozzle of medicine bottle is inserted the nostril, each every nostril 1-3 spray, 0.2 milliliter of every spray, spray 2-4 every day.5 routine patients are with the zinc-base Montmorillonitum spray of 5% (g/ml), and Therapeutic Method is same as described above, but 3 sprays must be sprayed in each every nostril, and 0.2 milliliter of every spray must be sprayed 4 every day.
The therapeutic evaluation standard clinical, recovery from illness: treat 48 hours normal with interior body temperature, symptom and sign disappears, and nothing is repeatedly.Produce effects: treat 48 hours normal with interior body temperature, inspections such as whole body poisoning symptom and laboratory make moderate progress, respiratory symptom changes, do not have recurrence.Effectively: it is normal to treat in 72 hours body temperature, and inspections such as whole body poisoning symptom and laboratory make moderate progress, respiratory symptom changes, do not have recurrence; Effectively: inspections such as 37.5 ℃-38.5 ℃ of body temperature, whole body poisoning symptom and laboratory make moderate progress, respiratory symptom does not have obvious change, symptom and sign recurrence; Invalid: symptom, sign and lab testing do not have change, use the other treatment method instead or sb.'s illness took a turn for the worse.
The result: 124 examples of fully recovering account for 52.1%; Produce effects 87 examples account for 36.6%; Effective 27 examples account for 11.3%, and invalid 0 example accounts for 0.0%, and effective percentage is 100%.
Experimental example 4: zinc-base smectite in treatment acute pharyngitis clinical trial.
Acute pharyngitis volunteer 42 examples, male's 18 examples, women's 24 examples, at 15～60 years old age, the course of disease is all within 7 days.
Clinical manifestation: primary symptom is that onset is more anxious, and pharyngeal drying is arranged earlier, scorching hot, harsh feeling, and the obvious pharyngalgia that continued, heavy especially during empty the pharynx, pain can be radiated to ear when lateral pharyngeal band was got involved.Sign: the congested swelling of the acute diffusivity of pars oralis pharyngis mucosa, pharynx rear wall lymph follicle protuberance, the outstanding heap soil or fertilizer over and around the roots hung down and the soft palate edema tonsil inflammation, submandibular lymph nodes enlargement tenderness.
Therapeutic Method: the patient looses with the zinc-base Montmorillonitum, is sprayed on pharyngeally, every day 3-4 time, uses continuously 7 days.
Efficacy evaluation: cure: symptom, sign complete obiteration; Produce effects: primary symptom, sign disappear and alleviate; Effectively: primary symptom, sign all take a favorable turn; Invalid: symptom, sign do not have change.
Result: cure 32 examples, account for 76.2%; Produce effects 4 examples account for 9.5%; 5 examples that take a turn for the better account for 11.9%, and invalid 1 example accounts for 2.4%, and total effective rate 97.6% is not seen untoward reaction.
Experimental example 5: zinc-base smectite in treatment vaginitis clinical trial.
Vaginitis patient volunteer 34 examples, at 18～55 years old age, course of disease 3d～1 is year surplus, non-pregnant non-lactation period.Clinical manifestation: pruritus vulvae, causalgia, leucorrhoea grow in quantity are the bean curd slag specimen, pudendum, vaginal mucosa hyperemia, redness, and the surface is with white membranoid substance.
Using method: the patient uses zinc-base Montmorillonitum suppository, and every contains zinc-base montmorillonite 2 gram, pushes vagina 3-5cm place, every day 1 time, uses continuously 7 days.
Efficacy evaluation: cure: clinical symptoms, sign complete obiteration; Produce effects: clinical symptoms obviously alleviates; Effectively: clinical symptoms, sign are improved; Invalid: clinical symptoms, sign do not have improvement.
Result: cure 25 examples, account for 73.5%; Produce effects 5 examples account for 14.7%; Effective 2 examples account for 5.9%; Invalid 2 examples account for 5.9%; Total effective rate 94.1% is not seen untoward reaction.
Experimental example 6: zinc-base smectite in treatment viral vaginitis clinical trial.
Herpetic vaginitis has herpes simplex virus to cause, is a kind of of viral vaginitis.The herpetic vaginitis patient of this experimental therapy volunteer 10 examples, the patient has heating, headache and vagina pain and burn feeling.Checking that visible vagina has erythema, is phlysis, pustule, the ulcer of substrate with the erythema.
Therapeutic Method: the patient is with the zinc-base montmorillonite gelling of 30% (g/ml), and each 3ml pushes vagina 3-5cm place every day each 1 time sooner or later, uses continuously 5 days, observe before the administration with administration after 2,3,4,5 days each patient's symptoms.
Efficacy evaluation: cure: clinical symptoms, sign complete obiteration; Produce effects: clinical symptoms obviously alleviates; Effectively: clinical symptoms, sign are improved; Invalid: clinical symptoms, sign do not have improvement.
Result: 2 days produce effects 3 examples, effective 4 examples, invalid 3 examples; Cured 4 examples, produce effects 3 examples, effective 3 examples, invalid 0 example in 3 days; Cured 7 examples, produce effects 3 examples, invalid 0 example in 4 days.Do not see untoward reaction.
Experimental example 7: zinc-base smectite in treatment oral ulcer clinical trial.
Oral ulcer patient's 36 examples, age 1-60 year, 1 of ulcer does not wait big person such as Semen Sojae Preparatum to several.Be divided into experimental group 19 examples at random, matched group 17 examples.
Experimental group looses with the zinc-base Montmorillonitum, dips in medicated powder with cotton swab and is applied to the affected part, and coating was not taken food or drunk water in 10 minutes, and every day, coating was 3-4 time, and matched group looses with Montmorillonitum, uses with quadrat method and is applied to the affected part.
Efficacy assessment standard, cure: pain obviously alleviates behind the coating 1d, and congestion and edema obviously disappears around the ulcer, and ulcer surface obviously dwindles, and ulcer heals fully behind the 3d; Effectively: congestion and edema disappears around the pain relief behind the 2d, ulcer, and the ulcer area dwindles, ulcer healing behind the 4d; Invalid: symptom no change behind the medication 5d, ulcer does not have improvement.
Experimental group is cured 16 examples (84.2%) as a result, effective 3 examples (15.8%), total effective rate 100%; Matched group is cured 8 examples (47%), effective 7 examples (41.2%), invalid 2 examples (11.8%), total effective rate (88.2%).Two groups of comparing differences have significance (P＜0.05).
Experimental example 8: zinc-base smectite in treatment acute infectious diarrhea clinical trial.
Acute infectious diarrhea 124 examples, wherein male 76 examples, woman's 48 examples, all meet the diagnostic criteria of acute infectious diarrhea in " Chinese diarrhoeal diseases diagnoses and treatment scheme ", be that onset is anxious, can change with heating, stool character, as loose stool, watery stool, mucus or bloody purulent stool, times of defecation every day is more than 3 times.The state of an illness is based on light medium-sized.Blood routine examination: leukocyte can increase or reduce, the visible leukocyte of stool routine or normal.The patient is divided into test group and matched group at random, test group 62 examples, matched group 62 examples.Two groups of cases state of an illness before age, sex, treatment is learned by statistics and is handled the difference not statistically significant, has comparability.
Therapeutic Method, two groups of patients all adopt the conventional therapies such as reaching fluid therapy of suiting the medicine to the illness.When taking above treatment, test group is obeyed with zinc-base Montmorillonitum raw edge, and matched group is obeyed with the Montmorillonitum raw edge.Two groups of dosage all are each 3 grams, every day 3 times.
Efficacy determination, produce effects: times of defecation and character recover normal in the treatment 72h, and General Symptoms disappears.Effectively: treatment 72h times of defecation and character are clearly better, and General Symptoms obviously improves.Invalid: treatment 72h times of defecation, character and General Symptoms all do not have improvement even worsen.
Result: test group total effective rate 96.4%, obvious effective rate 82.2%; Matched group total effective rate 84.2%, obvious effective rate 66.5%.Test group total effective rate and obvious effective rate obviously are better than matched group (P＜0.05).Test group symptom, sign used time that disappears obviously is less than matched group (P＜0.01).
Experimental example 9: zinc-base smectite in treatment epidermis ulcer clinical trial.
66 routine epidermis ulcer patients comprise that vascular ulcer, pressure ulcer, radiation ulcer, infective ulcer etc. meet the chronic skin ulcer standard, and the age is the personnel of 5-80 between year.Do not have other specific diseases, life is stable, and sanity cooperates the observer voluntarily.Be divided into two groups at random.33 examples are organized in treatment, male 18 examples, women 15 examples, age 15-76 (43.1 ± 1.2) year; Course of disease 30d-4 8 months (4.3 ± 2.4 months).Matched group 33 examples, male 17 examples, women 16 examples, age 14-77 (43.9 ± 1.4) year; Course of disease 30d-6 3 months (3.9 ± 2.3 months).2 groups of patients do not have significant difference between factors such as age, the course of disease.
Therapeutic Method, first routine disinfection wound circumference skin before changing dressings cleans a wound with normal saline, and purulent secretion more then cleans with hydrogenperoxide steam generator, cleans up surperficial secretions and slough as far as possible.The treatment group adopts the external application of zinc-base Montmorillonitum, according to the size of wound surface, gets the zinc-base montmorillonite gelling, places surgical dressing, spreads on wound surface then, and area coverage is greater than wound surface 0.5～1cm, every day or the next day change 1 time.The course of treatment: the ulcer 7-25d of no slough has the ulcer 20-60d of slough.Matched group Montmorillonitum external application, it is an amount of to get Montmorillonitum, normal saline furnishing pasty state places surgical dressing, spreads on wound surface then, area coverage is greater than wound surface 0.5～1cm, every day or the next day change 1 time.The course of treatment: the ulcer 7-25d of no slough has the ulcer 20-60d of slough.
Efficacy determination, recovery from illness: wound healing, clinical symptom disappearance.Produce effects: wound surface dwindles 75%, clinical symptom disappearance.Take a turn for the better: wound surface dwindles 25%, and clinical symptoms is improved.Invalid: wound surface dwindles less than 25%, and clinical symptoms does not have improvement.
The result: the treatment group is cured 27 examples, accounts for 81.8%, and produce effects 4 examples account for 12.1%, and 2 examples that take a turn for the better account for 6.1%, invalid 0 example, total effective rate 100%.Matched group is cured 6 examples, accounts for 18.2%, and produce effects 8 examples account for 24.2%, and 17 examples that take a turn for the better account for 51.5%, and invalid 2 examples account for 6.1%, total effective rate 93.9%.Two groups are compared zinc-base smectite in treatment epidermis ulcer significantly better than Montmorillonitum.
Embodiment 1:
Get Montmorillonitum 1000 grams of cation exchange capacity (CEC) for 71mmol/100g, add 15 times of water gagings, stir evenly, handled 120 minutes, add zinc sulfate (7 water zinc sulphate) 310 grams with the 40KHz ultrasonic echography, stirred 12 hours, after centrifugal the dewatering, divide equally 2 washings, dewater with 16 times of water gagings, 100 ℃ of oven dry, levigate promptly make the zinc-base Montmorillonitum.
Embodiment 2:
Get Montmorillonitum 1000 grams of cation exchange capacity (CEC), add 8 times of water gagings, stir evenly for 82mmol/100g, handle processing in 30 minutes with the 18KHz ultrasonic echography, add zinc chloride 215g, stirred 24 hours, after centrifugal the dewatering, wash with water repeatedly, centrifugal, be washed till washings and add silver nitrate solution and do not have precipitation, dewater, 100 ℃ of oven dry, levigate promptly make the zinc-base Montmorillonitum.
Embodiment 3:
Montmorillonitum has cation exchange, uses water-soluble zinc salts such as zinc nitrate, zinc gluconate, zinc citrate, and the preparation method with embodiment 1 or embodiment 2 has made the zinc-base Montmorillonitum equally.
Embodiment 4:
Get zinc-base Montmorillonitum 50 grams, add 800 milliliters in water, stir, handle with the 40KHz ultrasonic echography and handled in 15 minutes, add water again and make into 5% suspension, add sodium chloride and transfer osmotic pressure to ooze to waiting, behind the boiling sterilization, packing gets the zinc-base smectite turbid liquor.
Embodiment 5:
Get zinc-base montmorillonite 2 00 gram, add 900 milliliters in water, stir, handle with the 18KHz ultrasonic echography and handled in 60 minutes, add water again and make into 20% suspension, behind the boiling sterilization, packing gets the zinc-base smectite suspension agent.
Embodiment 6:
Get zinc-base Montmorillonitum 150 grams, add 500 milliliters in water, ethyl hydroxybenzoate 0.5 gram stirs, and handles with the 40KHz ultrasonic echography and handles in 30 minutes, adds sodium chloride and transfers osmotic pressure to ooze to waiting, and behind the autoclaving, packing gets the zinc-base montmorillonite gelling.
Embodiment 7:
Get zinc-base Montmorillonitum 300 grams, cocoa butter 200 grams add Montmorillonitum with the cocoa butter heat fused, and fully mixing is made 100 of suppositorys, promptly gets every suppository that contains zinc-base Montmorillonitum 3 grams.
Embodiment 8:
According to clinical needs, get the zinc-base Montmorillonitum, commonly used preparation method in the with medicament adds or does not add adjuvant, has made variable concentrations, the suspensoid of different size, gel, ointment, suppository, membrane, tablet and powder.
Claims (11)
1. a medicine for the treatment of infectious diseases is characterized in that with zinc-base smectite in treatment infectious disease.
2. a medicine for the treatment of infectious diseases is characterized in that being used for infectious disease such as zinc-base smectite in treatment upper respiratory tract infection, digestive tract infection, reproductive tract infection, skin infection.
3. according to a kind of medicine for the treatment of infectious diseases of claim 1 or 2, it is characterized in that the preparation method of zinc-base Montmorillonitum:, add entry with Montmorillonitum, stir evenly, use ultrasonic dispersing, add water-soluble zinc salt, the amount of zinc ion surpasses the ion exchange capacity of Montmorillonitum, stir, after centrifugal the dewatering, wash the acid group reaction of not having zinc salt to cleaning mixture with water, dewater, oven dry, levigate promptly makes the zinc-base Montmorillonitum.
4. according to a kind of medicine for the treatment of infectious diseases of claim 1 or 2, it is characterized in that, add 8-15 times of water gaging Montmorillonitum, stir evenly, handle with the 18-40KHz ultrasonic echography and handled in 30-120 minute, add water-soluble zinc salt, adding zinc ion amount is 1.5-3 a times of Montmorillonitum ion exchange capacity, stirred 12-24 hour, and after centrifugal the dewatering, washed with water 2-3 time, dewater, 100 ℃ of oven dry, levigate, promptly make the zinc-base Montmorillonitum.
5. according to a kind of medicine for the treatment of infectious diseases of claim 1 or 2, it is characterized in that pharmaceutical dosage form is suspensoid, gel, ointment, suppository, tablet and powder.
6. according to a kind of medicine for the treatment of infectious diseases of claim 1 or 2 or 5, it is characterized in that: with zinc-base smectite in treatment upper respiratory tract infection, its pharmaceutical dosage form is suspensoid, gel and powder; With zinc-base smectite in treatment digestive tract infection, its pharmaceutical dosage form is suspensoid, gel, tablet and powder; With zinc-base smectite in treatment reproductive tract infection, its pharmaceutical dosage form is suspensoid, gel, membrane, ointment and suppository; With zinc-base smectite in treatment skin infection, its pharmaceutical dosage form is suspensoid, gel, membrane, ointment and powder.
7. according to a kind of medicine for the treatment of infectious diseases of claim 1 or 2 or 5 or 6, it is characterized in that: the concentration of zinc-base smectite suspension agent, the content of zinc-base Montmorillonitum is the 5-20 gram in per 100 ml of formulation; The concentration of zinc-base montmorillonite gelling, the amount that contains the zinc-base Montmorillonitum in per 100 milliliters of zinc-base montmorillonite gellings are the 10-30 grams; Zinc-base Montmorillonitum suppository, every suppository contains zinc-base Montmorillonitum 0.5-3 gram.
8. according to a kind of medicine for the treatment of infectious diseases of claim 1 or 2 or 5 or 6, it is characterized in that: during with zinc-base smectite in treatment upper respiratory tract infection, suspensoid, gel can spray into nasal cavity or splash into nasal cavity in this way, also can splash into or spray into pharyngeal, each 1-3 spray, each spray 0.1-0.2 milliliter, in this way powder can spray into nasal cavity or spray into pharyngeal, every day 2-6 time.
9. according to a kind of medicine for the treatment of infectious diseases of claim 1 or 2 or 5 or 6, it is characterized in that: during with zinc-base smectite in treatment digestive tract infection, its suspensoid, gel, tablet and powder all are oral, each taking dose is to contain zinc-base Montmorillonitum 1-3 gram, every day 3 times.
10. according to a kind of medicine for the treatment of infectious diseases of claim 1 or 2 or 5 or 6, it is characterized in that: during with zinc-base smectite in treatment reproductive tract infection, its suspensoid, gel, ointment and suppository all are vagina medicinals, every day 1-2 time, every consumption is to contain zinc-base Montmorillonitum 0.5-3 gram.
11. a kind of medicine for the treatment of infectious diseases according to claim 1 or 2 or 5 or 6 is characterized in that: during with zinc-base smectite in treatment skin infection, its suspensoid, gel, membrane, ointment and powder all are in affected part local application, every day 1-2 time.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010112871A CN101773518A (en) | 2010-02-24 | 2010-02-24 | Medicine for treating infectious diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010112871A CN101773518A (en) | 2010-02-24 | 2010-02-24 | Medicine for treating infectious diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101773518A true CN101773518A (en) | 2010-07-14 |
Family
ID=42510193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010112871A Pending CN101773518A (en) | 2010-02-24 | 2010-02-24 | Medicine for treating infectious diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101773518A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102335191A (en) * | 2011-10-14 | 2012-02-01 | 济南康众医药科技开发有限公司 | Preparation method of compound medicament for treating diarrhea |
| CN104758310A (en) * | 2015-04-01 | 2015-07-08 | 山东司邦得制药有限公司 | Compounded montmorillonite-saccharose ointment and preparation method and application thereof |
| CN105030824A (en) * | 2015-08-20 | 2015-11-11 | 山东司邦得制药有限公司 | Application of zinc-based montmorillonite and calcium-based montmorillonite sterile styptic powder |
| CN105148316A (en) * | 2015-08-20 | 2015-12-16 | 山东司邦得制药有限公司 | Sterile zinc-based montmorillonite Band-Aid as well as preparation method and application thereof |
-
2010
- 2010-02-24 CN CN201010112871A patent/CN101773518A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102335191A (en) * | 2011-10-14 | 2012-02-01 | 济南康众医药科技开发有限公司 | Preparation method of compound medicament for treating diarrhea |
| CN104758310A (en) * | 2015-04-01 | 2015-07-08 | 山东司邦得制药有限公司 | Compounded montmorillonite-saccharose ointment and preparation method and application thereof |
| CN104758310B (en) * | 2015-04-01 | 2018-10-12 | 山东司邦得制药有限公司 | Compound montmorillonite sucrose ointment and its preparation method and application |
| CN105030824A (en) * | 2015-08-20 | 2015-11-11 | 山东司邦得制药有限公司 | Application of zinc-based montmorillonite and calcium-based montmorillonite sterile styptic powder |
| CN105148316A (en) * | 2015-08-20 | 2015-12-16 | 山东司邦得制药有限公司 | Sterile zinc-based montmorillonite Band-Aid as well as preparation method and application thereof |
| CN105030824B (en) * | 2015-08-20 | 2017-11-10 | 山东司邦得制药有限公司 | A kind of application of zinc-base montmorillonite and the sterile styptic powder of ca-montmorillonite |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101773518A (en) | Medicine for treating infectious diseases | |
| CN110787202A (en) | Wind-dispelling and collateral-activating oil | |
| CN102755559B (en) | Traditional Chinese medicine composition for treating non-gonococcal urethritis | |
| CN104095970B (en) | A kind of External apply medicinal wine for the treatment of verruca vulgaris | |
| CN103405653B (en) | External preparation for treating gouty arthritis | |
| CN102872300B (en) | Traditional Chinese medicine for treating non-gonococcal urethritis | |
| CN102552665B (en) | Externally-applied traditional Chinese medicine composition for treating gynecological diseases | |
| CN103920076A (en) | Traditional Chinese medicine for treating tinea of feet and hands as well as eczema | |
| CN100348239C (en) | Chinese traditional medicine for curing soft tissue pains and process for preparing the same | |
| CN102697925A (en) | Traditional Chinese medicine combination for treating aural eczema | |
| CN102416064A (en) | Medicament for treating ulcerated chilblain | |
| CN102846750B (en) | Fengtongning composite preparation and preparation method thereof | |
| CN104815092A (en) | Traditional Chinese medicine composition for treating chronic pelvic inflammation | |
| CN105616731A (en) | Method for treating chronic pelvic inflammation by using combination of enteroclysis with traditional Chinese medicine sargentodoxa vine decoction and microwave intracavitary physiotherapy | |
| CN102366567B (en) | Pharmaceutical composition for treating condyloma acuminatum, and preparation and application method | |
| CN104288570B (en) | A kind of Chinese medicine for preventing and treating bleeding from five sense organs or subcutaneous tissue | |
| CN103110748B (en) | Compound traditional Chinese medicine composite of a kind for the treatment of venereal and uses thereof | |
| CN106822714A (en) | A kind of gynaecological gel and preparation method thereof | |
| CN106491780A (en) | A kind of treat Chinese medicine composition of gout and preparation method thereof | |
| CN110064003A (en) | A kind of traditional Chinese medicine composition for herpes and preparation method thereof | |
| CN104306819B (en) | It is a kind of to treat Chinese medicine composition of NUG and preparation method thereof | |
| CN1248723C (en) | Displaying and curing liquor for rheumatism | |
| CN105126050A (en) | Traditional Chinese medicinal composition for treating urinary calculus and preparation method of traditional Chinese medicinal composition | |
| CN104688954B (en) | A kind of Chinese medicine for treating menorrhalgia of cold-stagnation and blood-stasis type | |
| CN101199624B (en) | Tincture medicament for treating psoriasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20100714 |